Study on Phenylethylamines New Compounds Against Benign Prostatic Hyperplasia

WANG Rong-rong,JIANG Zhen-zhou,XI Bao-min,WANG Tao,LIU Jing,HANG Zhong-liang,ZHANG Lu-yong
2009-01-01
Abstract:AIM:To study the bioactivities in vitro and the pharmacodynamic action in vivo of XBM series phenylethylamines as α1-adrenocepter antagonist on benign prostatic hyperplasia.METHODS: The antagonism of XBMs on isolated SD rat anococcygeus musle was observed by isometric tension experiment.The adrenoceptor subtype selectivity of XBM-21 was identified by flow cytometry,and the effect of XBM-21 on benign prostatic hyperplasia model rats was also identified.RESULTS: Most of the XBM new compounds have antagonism on α1-AR,the pA2 of XBM-21 was 8.42.The IC50 of XBM-21 on α1A-AR,α1B-AR and α1D-AR were 71.5 nmol/L,1.03 μmol/L and 65 nmol/L,respectively.XBM-21 could obviously improve the dry and humid weight index of hyperplasia of prostate gland model rats.CONCLUSION:XBM-21 has siginificant antagonism on blocking α1-adrenoceptor,it has good selectivities on α1A-AR and α1D-AR,which indicateed the new compound could better improve the symptom induced by benign prostatic hyperplasia.
What problem does this paper attempt to address?